Filing Flows › Comparisons › TXG vs CTKB
10x Genomics vs Cytek Biosciences: TXG and CTKB compared
10x Genomics is the larger company: $151M of revenue in its latest quarter (Q3 2026) against $53.2M for Cytek Biosciences (Q3 2026). Cytek Biosciences is growing faster (+2% against +1% a year earlier). 10x Genomics is more profitable, with an operating margin of -10.7% against -15.8%.
Where the money goes: TXG and CTKB
10x Genomics (TXG) · Q3 2026
10x Genomics, Q3 2026: revenue $151M (+1% year over year), operating margin -10.7%, net loss $19.4M, operating cash flow $15.8M. The chart follows the revenue to costs, profit and cash.
Cytek Biosciences (CTKB) · Q3 2026
Cytek Biosciences, Q3 2026: revenue $53.2M (+2% year over year), operating margin -15.8%, net loss $6.1M, operating cash flow −$4.5M. The chart follows the revenue to costs, profit and cash.
| 10x Genomics (TXG) | Cytek Biosciences (CTKB) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $151M | $53.2M |
| Revenue growth, Y/Y | +1% | +2% |
| Operating margin | -10.7% | -15.8% |
| Net earnings | −$19.4M | −$6.1M |
| Net margin | -12.9% | -11.5% |
| Operating cash flow | $15.8M | −$4.5M |
| Free cash flow | $14.9M | — |
Where the revenue comes from
10x Genomics
- Consumables: $134M (89%)
- Services: $9.0M (6%)
- Instruments: $6.9M (5%)
Cytek Biosciences
- Product: $37.2M (70%)
- Service: $16.1M (30%)
Questions
Which is bigger, 10x Genomics or Cytek Biosciences?
10x Genomics is the larger company: $151M of revenue in its latest quarter (Q3 2026) against $53.2M for Cytek Biosciences (Q3 2026).
Is 10x Genomics or Cytek Biosciences growing faster?
Cytek Biosciences is growing faster (+2% against +1% a year earlier).
Which is more profitable, 10x Genomics or Cytek Biosciences?
10x Genomics is more profitable, with an operating margin of -10.7% against -15.8%.
More: 10x Genomics earnings · how 10x Genomics makes money · Cytek Biosciences earnings · how Cytek Biosciences makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 6, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.